A trial looking at tabalumab for myeloma (JDCG)

This trial is looking at a new drug called tabalumab alongside bortezomib and dexamethasone for myeloma that has come back after treatment.

Doctors often treat myeloma with chemotherapy and biological therapies. If myeloma comes back, doctors may treat it with a biological therapy drug called bortezomib. They may also use a drug called dexamethasone.

Tabalumab is another type of biological therapy called a monoclonal antibody. It seeks out myeloma cells by looking for a particular protein.

The researchers think that combining tabalumab with bortezomib and dexamethasone may be better than bortezomib and dexamethasone alone for people whose myeloma has come back.

The aims of this trial are to find out

• How much tabalumab to give

• How well tabalumab combined with bortezomib and dexamethasone works

• What the side effects are